← Back

Wire · opportunities

Korean biotech Quracle seeks U.S. Phase 2b trial of CU06 in 156 DME patients

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at thepharmanews.net →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Quracle, a Korean biotech firm, has applied to the U.S. FDA to conduct a Phase 2b clinical trial of its oral drug CU06 (Rivasterat) for diabetic macular edema, enrolling 156 patients to evaluate visual acuity improvements over 24 weeks.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your drug development in retinal diseases can now access a less invasive oral therapy pathway in the U.S. starting Phase 2b trials. This opens a chance to sidestep injection-based treatments and attract patients seeking convenience.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialbiotechophthalmologyFDAdrug-development